Skip to content

Cognitive-behavioral Therapy for Mental Disorder in COVID-19 Survivors

Evaluate the Effectiveness for Long-term Consequences of COVID-19 of Mindfulness-based Stress Reduction (MBSR)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05815693
Acronym
LONGCOVID
Enrollment
140
Registered
2023-04-18
Start date
2023-04-13
Completion date
2023-11-30
Last updated
2023-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Acute COVID-19 Syndrome

Brief summary

The consequences of the Intensive Care Unit and the Covid-19 disease are still uncertain. However, many studies are bringing out often psychological and dramatic consequences for many COVID-survivor patients. Among the ex-covid patients discharged from our Intensive Care Unit and with at least one covid-related psychological consequence, we want to evaluate the effectiveness for long-term consequences of COVID-19 of mindfulness-based stress reduction (MBSR) or usual care.

Detailed description

Randomized controlled clinical study. All patients who survived COVID-19 and discharged from the intensive care unit of the Lecco hospital will be enrolled if present: chronic pain, anxiety, depression and/or insomnia in pharmacological therapy A group of patients will be observed during 12 months and evaluated with rating scales for chronic pain, anxiety, depression and insomnia. The second (experimental) group will receive psychotherapy (mindfulness-based stress reduction and cognitive behavioral therapy) in addition to the pharmacological therapy

Interventions

BEHAVIORALmindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT)

Patients with long-term consequences of COVID-19 (Chronic pain, anxiety, depression or insomnia) enrolled and randomly assigned to receive MBSR (n = 63), or usual care (n = 62). MBSR (training in mindfulness meditation and yoga) were delivered in 12 months with 2-hour groups each 2 months. Usual care included anything care participants received such as drug therapy.

Sponsors

Azienda Socio Sanitaria Territoriale di Lecco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Intensive care survivors * Surviving COVID-19 patients * Patients with Chronic Pain Anxiety Depression and/or Insomnia in drug therapy

Exclusion criteria

* Patients with Chronic Pain Anxiety Depression and/or Insomnia NOT in drug therapy * Patients not hospitalized in intensive care for COVID-19

Design outcomes

Primary

MeasureTime frameDescription
Chronic pain6 months and 1 yearpain that persists or recurs for longer than 3 months, and it exerts an enormous personal and economic burden, affecting more than 30% of people worldwide
Anxiety6 months and 1 yearan emotion characterized by feelings of tension, worried thoughts, and physical changes like increased blood pressure
Depression6 months and 1 yeara depressed mood or loss of pleasure or interest in activities for long periods of time
Insomnia6 months and 1 yeara common sleep disorder that can make it hard to fall asleep, hard to stay asleep, or cause you to wake up too early and not be able to get back to sleep

Countries

Italy

Contacts

Primary ContactVincenzo LC Damico, PhD
vi.damico@asst-lecco.it+39 3409297118

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026